Ocean Biomedical receives Nasdaq delisting determination for missing filing deadlines

Ocean Biomedical, Inc.

Nasdaq notified company on Oct 16, 2024 that it failed to file Form 10-K for 2023 and Forms 10-Q for Q1 and Q2 2024.
Exception granted until Oct 14, 2024 was not met; company has not filed the required reports.
Company will appeal the Staff determination to a Nasdaq Hearings Panel under Rule 5800 Series.
Ticker OCEA and OCEAW remain listed pending appeal; outcome uncertain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.